Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | NPC1 | O15118 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.68 |
| ▸ | RELA | Q04206 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ACACA | Q13085 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | TACR3 | P29371 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26613511 | 0.89 | KDM4E (0.72) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL30228475 | 0.88 | KDM4E (0.66) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL5682765 | 0.88 | KDM4E (0.66) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL29276997 | 0.83 | NPC1 (0.59) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL29636725 | 0.81 | NPC1 (1.00) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL28596277 | 0.81 | SMN1; SMN2 (0.66) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL707767 | 0.81 | NPC1 (1.00) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL29501311 | 0.81 | SMN1; SMN2 (0.66) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL6851588 | 0.80 | RAB9A (0.69) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL29746123 | 0.80 | RAB9A (0.69) | KDM4ESMN1; SMN2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117229204-A | Method for preparing quinoline derivative by catalytic conversion of lignin by rhodium-based catalyst | 中国科学院大连化学物理研究所 | 2023-12-15 | — | — | CN | disclosed |
| CN-102924458-B | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARM INC | 2014-11-05 | — | — | CN | disclosed |
| CN-102924458-A | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARM INC | 2013-02-13 | — | — | CN | disclosed |
| US-7820662-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| CN-101273038-A | Macrocylic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2008-09-24 | — | — | CN | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| CN-1960993-A | 6, 6-bicyclic substituted heterobicyclic protein kinase inhibitors | OSI PHARM INC (US) | 2007-05-09 | — | — | CN | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
| US-5627193-A | MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1997-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | KDM4E 2218/4885SMN1; SMN2 2622/4885ALDH1A1 3941/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | KDM4E 2218/4885SMN1; SMN2 2622/4885ALDH1A1 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.